Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?

Novo Nordisk issued troubling guidance for 2026, warning revenue could fall by as much as 13% for the current year; shares have lost over 50% in the past 12 months and plunged on the guidance. Management cites pricing pressure, a new CEO, and expects market-share recovery via lower prices; the company launched an oral Wegovy and struck a distribution deal with Hims & Hers to sell GLP-1 products. The stock trades at roughly 10x earnings, indicating a deep valuation discount, but near-term volatility and company-specific downside remain likely.

Analysis

Price concessions to expand access will compress near-term unit economics but have an asymmetric payoff: if share gains come mainly from lower-acquisition cohorts accessed via telehealth, lifetime value per customer may be materially below legacy chronic-care patients, making reported revenue growth a poor proxy for durable profit growth. The distribution move into low-friction channels (telehealth/retail) accelerates penetration but increases churn, reduces average treatment duration, and makes cohort-level unit economics critical to model over the next 12–24 months.

Second-order supply effects favor large-scale peptide manufacturers and firms with integrated fill/finish and peptide synthesis capabilities; smaller CMOs will struggle to match incremental volume without meaningful capex, which should raise fixed-cost intensity across the supply chain. Payers will use broader distribution data to tighten step-therapy and prior-authorization rules — that dynamic can compress realized price faster than headline ASPs suggest and will be most visible in 2–4 formulary cycles.

Time horizons matter: expect volatility over days/weeks around quarterly reads and distribution rollouts, but structural outcomes (durable share, payer concessions, margin normalization) will play out over 6–24 months. Tail risks include a sustained price war, adverse regulatory scrutiny of new distribution channels, or faster-forcing competitive launches; conversely, realization of cost-outs or higher-than-expected retention would re-rate fundamentals quickly.

The market may be overstating permanent demand destruction while understating how quickly new-channel economics can reveal sub-scale unit margins. That makes a barbell approach sensible: short-duration instruments to capture negative near-term re-rating, combined with selectively sized longer-dated directional exposure if management demonstrates retention and payer wins in the next two formulary cycles.

Key Decisions for Investors

• Pair trade (3–9 months): Long HIMS equity or 9–12 month call options (expressing distribution monetization) sized 1–1.5% NAV paired with short NVO via a 3–6 month put spread (buy 1x 15% OTM put, sell 1x 30% OTM put to offset premium) sized 0.75–1% NAV to capture asymmetric distribution upside vs margin squeeze. Target: 25–40% relative return if HIMS adoption accelerates; stop-loss: 20% adverse move in either leg.
• Capital-efficient hedge (6 months): Buy NVO 6-month 10–20% OTM put spread (caps cost) sized 1% NAV as insurance against further near-term re-rating; cost should be <1.5% NAV and protects against a >15% drop in the underlying. Exit/roll if put spread >2.5x cost or after next two earnings releases show stabilization.
• Tactical long HIMS (6–12 months): Buy HIMS shares or 12-month calls sized 0.5–1% NAV to play volume monetization and higher LTV from telehealth channels; target 30–50% upside if channel economics are positive. Use a 25% trailing stop or hedge by selling short-dated calls to finance carry if conviction is medium.
• Risk management rule: Keep net directional NVO exposure <1.5% NAV and use option structures to define downside; re-evaluate after two sequential quarters of retention/payer metrics before adding long-duration risk.
• Alert setup: Monitor three catalysts — (1) next two quarters’ retention rates by channel, (2) payer formulary changes over next 6–12 months, (3) manufacturing utilization/cost disclosures. Any signal of retention > baseline or meaningful capacity-driven cost-outs should trigger trimming put hedges and redeploying into longer-dated LEAPs.